TherapeuticsMD, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(Unaudited - in thousands)

	Six Months Ended June 30,
	2025	2024
Cash flows from operating activities:
Net loss	$(102)	$(1,824)
Less: (loss) income from discontinued operations, net of income taxes	(11)	35
Net loss from continuing operations	(91)	(1,859)
Adjustments to reconcile net loss to net cash provided by continuing operating activities:
Depreciation and amortization	191	313
Impairment of long-lived assets (Note 4)	—	1,261
Write-off of patents and trademarks	88	—
Share-based compensation	24	207
Other	370	376
Changes in operating assets and liabilities:
Other assets	872	1,260
Prepaid and other current assets	(192)	534
Accounts payable	92	116
Accrued expenses and other current liabilities	84	(457)
Lease liabilities	(445)	(528)
Other non-current liabilities	87	1
Total adjustments	1,171	3,083
Net cash provided by continuing operating activities	1,080	1,224
Discontinued operations:
Net cash used in operating activities	(70)	(319)
Net cash used in discontinued operations	(70)	(319)
Net increase in cash	1,010	905
Cash and cash equivalents - continuing operations, beginning of period	5,059	4,327
Total cash and cash equivalents, end of period	$6,069	$5,232

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.